Pfizer-BioNTech said a three-shot course of their Covid-19 vaccine was able to neutralise the Omicron variant in a laboratory test and an upgraded vaccine for the new strain could be ready by March 2022.
Dec 8 (Reuters) - BioNTech and Pfizer (PFE.N) said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test, an early signal that booster shots could be key to protection against infection from the newly identified variant. The German.